登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，3月20日，Estimating the Risks from COVID-19 Infection in Adult Chemotherapy Patients》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-22

  • Estimating the Risks from COVID-19 Infection in Adult Chemotherapy Patients

    Matt Williams, Kerlann Le Calvez, Ella Mi, Jiarong Chen, Seema Dadhania, Lillie Pakzad-Shahabi

    doi: https://doi.org/10.1101/2020.03.18.20038067

    Abstract

    The SARS-CoV-2 (COVID-19) novel coronavirus represents a significant health risk, particularly in older patients. Cancer is one of the leading causes of death in most rich countries, and delivering chemotherapy may be associated with increased risk in the presence of a pandemic infection. Estimating this risk is crucial in making decisions about balancing risks and benefits from administering chemotherapy. However, there are no specific data about chemotherapy risks per se. Here we develop a simple model to estimate the potential harms in patients undergoing chemotherapy during a COVID outbreak.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.03.18.20038067v1
45浏览量
原文链接
相关报告

  • 《MedRxiv，3月20日，Estimating Spot Prevalence of COVID-19 from Daily Death Data in Italy》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-22
    • Estimating Spot Prevalence of COVID-19 from Daily Death Data in Italy Ali Raheem doi: https://doi.org/10.1101/2020.03.17.20037697 Abstract COVID-19 like many infectious diseases has a variable severity. Due to limited testing capacity for new virus, the majority of infected showing mild or no symptoms it is likely current prevalence data is an underestimate. We present an estimate of the point prevalence of COVID-19 compared to the number of confirmed case in Italy based on the daily death rate and information about the incubation period, time from symptom onset to death and reported case fatality rate. Our model predicts that when the first 3 infected cases had been identified by Italian authorities there were already nearly 30 cases in Italy, and by the 24th of February 2020 only 0.5% cases had been detected and confirmed by Italian authorities. While official statistics had 132 confirmed case we believe a more accurate estimate would be closer to 26000. With a case-doubling period of about 2.5 days. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    83浏览量
    原文链接

  • 《MedRxiv，3月20日，SARS-CoV-2 specific antibody responses in COVID-19 patients》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-22
    • SARS-CoV-2 specific antibody responses in COVID-19 patients NISREEN M.A. OKBA, Marcel A Muller, Wentao Li, Chunyan Wang, Corine H. GeurtsvanKessel, Victor M. Corman, Mart M. Lamers, Reina S. Sikkema, Erwin de Bruin, Felicity D. Chandler, Yazdan Yazdanpanah, Quentin Le Hingrat, Diane Descamps, Nadhira Houhou-Fidouh, Chantal B. E. M. Reusken, Berend-Jan Bosch, Christian Drosten, Marion P.G. Koopmans, Bart L. Haagmans doi: https://doi.org/10.1101/2020.03.18.20038059 Abstract A new coronavirus, SARS-CoV-2, has recently emerged to cause a human pandemic. Whereas molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are important for contact tracing, identifying the viral reservoir and epidemiological studies. Here, we developed serological assays for the detection of SARS-CoV-2 neutralizing, spike- and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed infections of SARS-CoV-2, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    130浏览量
    原文链接